By Fineline Cube Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its development partner Caldera Therapeutics has entered into a definitive merger agreement with Synlogic (OTCMKTS: SYBX) to combine in an all-stock transaction, creating a unified entity that will operate as Caldera Therapeutics, Inc. and trade on the Nasdaq Capital Market under ticker “CALD”. The merger is supported by a concurrent private placement financing of approximately $278 million from a syndicate of leading healthcare investors, which will fund Phase II clinical development of QX030N/CLD-423 – Qyuns’ investigational bispecific antibody targeting TL1A and IL-23p19 pathways for inflammatory bowel disease (IBD).
Transaction Structure
| Item | Detail |
|---|---|
| Merger Type | All-stock transaction |
| Combined Entity | Caldera Therapeutics, Inc. (NASDAQ: CALD) |
| Financing Amount | $278 million gross proceeds (concurrent private placement) |
| Lead Investors | Bain Capital Life Sciences, TCGX, Atlas Venture, venBio Partners, Omega Funds, Blackstone Multi-Asset Investing, LAV, Wellington Management, Janus Henderson Investors, Sirenia Capital, Vivo Capital, plus additional mutual funds and institutional investors |
| Primary Use of Proceeds | Phase II development of QX030N/CLD-423 in ulcerative colitis and Crohn’s disease; potential expansion to other immune-mediated diseases |
| Qyuns Stake | 11.48% ownership in combined entity (diluted from 24.88% following Series A-1 financing) |
Asset Profile & Development Strategy
- Lead Candidate: QX030N/CLD-423 – investigational bispecific antibody with dual mechanism of action
- Target Pathways: Simultaneous inhibition of TL1A (TNFSF15) and IL-23p19, two clinically validated targets in IBD pathogenesis
- Therapeutic Indications: Ulcerative colitis, Crohn’s disease, and potential expansion to other immune-mediated inflammatory conditions
- Development Stage: Advancing to Phase II clinical trials with substantial funding support
- Commercial Rights: Global exclusive rights granted to Caldera under April 2025 collaboration agreement
Strategic Rationale & Market Opportunity
The global inflammatory bowel disease market is projected to reach $25 billion by 2030, driven by increasing incidence rates, limited treatment durability, and significant unmet needs in refractory patients. Current biologic therapies primarily target single pathways (TNF-α, IL-12/23, integrins, or JAK), but primary non-response and secondary loss of response remain major clinical challenges.
Dual pathway inhibition represents a promising next-generation approach to overcome these limitations:
- TL1A pathway drives fibrosis and stricturing complications in Crohn’s disease
- IL-23 pathway is central to Th17-mediated inflammation in both UC and CD
- Simultaneous blockade may provide superior efficacy and prevent compensatory inflammatory mechanisms
The merger creates a well-capitalized entity with:
- Substantial cash runway ($278M financing) supporting multi-year development
- Enhanced credibility through public listing on Nasdaq
- Access to broader investor base and potential partnership opportunities
- Operational scale to advance multiple development programs
Qyuns Therapeutics Positioning
- Strategic Investment: Qyuns holds 11.48% equity stake in the combined entity, providing significant upside exposure to asset success
- Royalty Stream: Retains royalty rights on global sales of QX030N/CLD-423 while transferring development costs and risks
- Portfolio Diversification: Maintains focus on core pipeline while benefiting from partner-funded advancement of IBD asset
- Capital Efficiency: Achieves de-risked value creation without bearing full development burden
Investor Syndicate Significance
The exceptionally strong investor lineup validates the therapeutic approach and commercial potential:
- Bain Capital Life Sciences – leading life sciences-focused private equity firm
- Atlas Venture – prominent early-stage biotech venture capital firm
- Wellington Management & Janus Henderson – major mutual fund complexes with healthcare expertise
- Specialized IBD investors including venBio Partners and Omega Funds with deep therapeutic area knowledge
This level of institutional support suggests high confidence in the dual-pathway hypothesis and robust clinical data packages supporting Phase II advancement.
Next Steps & Timeline
- Merger Closing: Expected within 60-90 days subject to regulatory approvals and shareholder consents
- Phase II Initiation: Clinical trial start anticipated in Q1 2027 with primary endpoints focused on clinical remission and endoscopic improvement
- Regulatory Strategy: Engage with FDA and EMA on trial design and potential accelerated approval pathways
- Additional Indications: Evaluate expansion into other TL1A/IL-23 mediated diseases including psoriasis, ankylosing spondylitis, and hidradenitis suppurativa
Forward‑Looking Statements
This brief contains forward-looking statements regarding merger completion, clinical development timelines, regulatory strategies, and financial projections. Actual results may differ due to risks including merger integration challenges, clinical trial outcomes, regulatory requirements, competitive developments, and capital market conditions.-Fineline Info & Tech